Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed-Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities
Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed-Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities